EE200100641A - Pürasinooniühendid, trombiini inhibeeriv farmatseutiline kompositsioon ja meetod trombitekke inhibeerimiseks veres - Google Patents

Pürasinooniühendid, trombiini inhibeeriv farmatseutiline kompositsioon ja meetod trombitekke inhibeerimiseks veres

Info

Publication number
EE200100641A
EE200100641A EEP200100641A EEP200100641A EE200100641A EE 200100641 A EE200100641 A EE 200100641A EE P200100641 A EEP200100641 A EE P200100641A EE P200100641 A EEP200100641 A EE P200100641A EE 200100641 A EE200100641 A EE 200100641A
Authority
EE
Estonia
Prior art keywords
inhibiting
pharmaceutical composition
thrombin
blood thrombosis
compounds
Prior art date
Application number
EEP200100641A
Other languages
English (en)
Estonian (et)
Inventor
S. Burgey Christopher
A. Robinson Kyle
D. Williams Peter
A. Coburn Craig
A. Lyle Terry
E. Sanderson Philip
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of EE200100641A publication Critical patent/EE200100641A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • C07D213/71—Sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/16—Halogen atoms; Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EEP200100641A 1999-06-04 2000-06-01 Pürasinooniühendid, trombiini inhibeeriv farmatseutiline kompositsioon ja meetod trombitekke inhibeerimiseks veres EE200100641A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13753899P 1999-06-04 1999-06-04
US14429199P 1999-07-16 1999-07-16
PCT/US2000/015140 WO2000075134A1 (fr) 1999-06-04 2000-06-01 Inhibiteurs de thrombine a base de pyrazinone

Publications (1)

Publication Number Publication Date
EE200100641A true EE200100641A (et) 2003-02-17

Family

ID=26835338

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100641A EE200100641A (et) 1999-06-04 2000-06-01 Pürasinooniühendid, trombiini inhibeeriv farmatseutiline kompositsioon ja meetod trombitekke inhibeerimiseks veres

Country Status (31)

Country Link
US (1) US6455532B1 (fr)
EP (1) EP1189899B1 (fr)
JP (2) JP4495377B2 (fr)
KR (1) KR20020029653A (fr)
CN (1) CN1353705A (fr)
AT (1) ATE232527T1 (fr)
AU (1) AU761982B2 (fr)
BG (1) BG106263A (fr)
BR (1) BR0011260A (fr)
CA (1) CA2373999C (fr)
CZ (1) CZ20014343A3 (fr)
DE (1) DE60001414T2 (fr)
DK (1) DK1189899T3 (fr)
DZ (1) DZ3264A1 (fr)
EA (1) EA004372B1 (fr)
EE (1) EE200100641A (fr)
ES (1) ES2190417T3 (fr)
HK (1) HK1047277A1 (fr)
HR (1) HRP20010903A2 (fr)
HU (1) HUP0202366A3 (fr)
IL (1) IL146393A0 (fr)
IS (1) IS6158A (fr)
MX (1) MXPA01012505A (fr)
NO (1) NO20015887L (fr)
NZ (1) NZ515454A (fr)
PL (1) PL352558A1 (fr)
SK (1) SK17532001A3 (fr)
TR (1) TR200103491T2 (fr)
UA (1) UA58636C2 (fr)
WO (1) WO2000075134A1 (fr)
YU (1) YU84301A (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001265094A1 (en) 2000-06-01 2001-12-11 Merck And Co., Inc. Pyrazinone thrombin inhibitors
FR2818277B1 (fr) * 2000-12-14 2003-01-24 Servier Lab Nouveaux derives bicycliques d'amino-pyrazinones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6528503B2 (en) 2000-12-18 2003-03-04 Merck & Co., Inc. Thrombin inhibitors
WO2002050056A1 (fr) 2000-12-18 2002-06-27 Merck & Co., Inc. Derives de benzylamine et leur utilisation comme inhibiteurs de thrombine
US7144899B2 (en) 2001-02-09 2006-12-05 Merck & Co., Inc. Thrombin inhibitors
US7262211B2 (en) 2001-12-04 2007-08-28 Dendreon Corporation Aromatic heterocyclic non-covalent inhibitors of urokinase and blood vessel formation
FR2867780B1 (fr) * 2004-03-19 2006-05-19 Servier Lab Nouveaux derives de 4-oxo-4,6,7,8-tetrahydropyrrolo (1,2-a) pyrazine-6-carboxamides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE102004022897A1 (de) * 2004-05-10 2005-12-08 Bayer Cropscience Ag Azinyl-imidazoazine
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
DE102008041214A1 (de) 2008-08-13 2010-02-18 Bayer Cropscience Ag N-substituierte Azinylakyl-azincarboxamide und deren Analoge
WO2011056806A1 (fr) * 2009-11-03 2011-05-12 Diakron Pharmaceuticals, Inc. Procédé de préparation d'un inhibiteur de thrombine pyrazinone et ses intermédiaires
CA2857953A1 (fr) 2011-11-07 2013-05-16 Diakron Pharmaceuticals Inc. Formulation a liberation prolongee d'un inhibiteur direct de thrombine
CN115677511B (zh) * 2022-10-26 2024-06-21 南通华祥医药科技有限公司 一种2,2-二氟丙胺盐酸盐的合成方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4795486A (en) 1986-09-26 1989-01-03 Boehner Beat Aminopyrazinones and aminotriazinones
TW201303B (fr) 1990-07-05 1993-03-01 Hoffmann La Roche
GB9207145D0 (en) 1991-04-18 1992-05-13 Ici Plc Heterocyclic amides
CN1038586C (zh) 1991-05-01 1998-06-03 大制药株式会社 吡嗪衍生物的制备方法
DE4127404A1 (de) 1991-08-19 1993-02-25 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
TW223629B (fr) 1992-03-06 1994-05-11 Hoffmann La Roche
US5672582A (en) 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
AU670381B2 (en) 1993-04-30 1996-07-11 Merck & Co., Inc. Thrombin inhibitors
US5510369A (en) 1994-07-22 1996-04-23 Merck & Co., Inc. Pyrrolidine thrombin inhibitors
EP0820453A4 (fr) 1995-04-04 2001-08-29 Merck & Co Inc Inhibiteurs de thrombine
US5629324A (en) 1995-04-10 1997-05-13 Merck & Co., Inc. Thrombin inhibitors
WO1997001338A1 (fr) * 1995-06-27 1997-01-16 Merck & Co., Inc. Inhibiteurs de la thrombine a base de pyridinone
PL329441A1 (en) * 1996-04-23 1999-03-29 Merck & Co Inc Pyrasinone-type thrombin inhibitors
US5668289A (en) 1996-06-24 1997-09-16 Merck & Co., Inc. Pyridinone thrombin inhibitors
US5981546A (en) 1996-08-29 1999-11-09 Merck & Co., Inc. Integrin antagonists
JP2001508796A (ja) * 1997-01-22 2001-07-03 メルク エンド カンパニー インコーポレーテッド トロンビン阻害薬
CA2283704A1 (fr) * 1997-03-24 1998-10-01 Merck & Co., Inc. Inhibiteurs de thrombine
US5866573A (en) 1997-04-21 1999-02-02 Merck & Co., Inc. Pyrazinone thrombin inhibitors
EP1017393A4 (fr) 1997-09-05 2002-01-23 Merck & Co Inc Inhibiteurs de thrombine a base de pyrazinone
AU753479B2 (en) * 1998-05-19 2002-10-17 Merck & Co., Inc. Pyrazinone thrombin inhibitors
PL352368A1 (en) 1999-05-19 2003-08-25 Pharmacia Corp Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade

Also Published As

Publication number Publication date
US6455532B1 (en) 2002-09-24
NO20015887D0 (no) 2001-12-03
JP4495377B2 (ja) 2010-07-07
TR200103491T2 (tr) 2002-12-23
EA200200005A1 (ru) 2002-06-27
EP1189899A1 (fr) 2002-03-27
UA58636C2 (uk) 2003-08-15
BR0011260A (pt) 2002-03-19
PL352558A1 (en) 2003-08-25
EA004372B1 (ru) 2004-04-29
ES2190417T3 (es) 2003-08-01
DK1189899T3 (da) 2003-03-10
BG106263A (en) 2002-06-28
HUP0202366A2 (en) 2002-10-28
CA2373999C (fr) 2007-01-02
CN1353705A (zh) 2002-06-12
DZ3264A1 (fr) 2000-12-14
YU84301A (sh) 2004-07-15
HRP20010903A2 (en) 2003-04-30
SK17532001A3 (sk) 2002-05-09
CA2373999A1 (fr) 2000-12-14
KR20020029653A (ko) 2002-04-19
NZ515454A (en) 2004-02-27
IL146393A0 (en) 2002-07-25
HUP0202366A3 (en) 2005-07-28
HK1047277A1 (zh) 2003-02-14
AU5457100A (en) 2000-12-28
MXPA01012505A (es) 2002-07-02
ATE232527T1 (de) 2003-02-15
NO20015887L (no) 2002-01-23
DE60001414D1 (en) 2003-03-20
CZ20014343A3 (cs) 2002-03-13
DE60001414T2 (de) 2003-11-06
IS6158A (is) 2001-11-13
JP2010150275A (ja) 2010-07-08
EP1189899B1 (fr) 2003-02-12
WO2000075134A1 (fr) 2000-12-14
AU761982B2 (en) 2003-06-12
JP2003501426A (ja) 2003-01-14

Similar Documents

Publication Publication Date Title
EE200100641A (et) Pürasinooniühendid, trombiini inhibeeriv farmatseutiline kompositsioon ja meetod trombitekke inhibeerimiseks veres
BR9908004A (pt) Composto, composição e método para prevençãoou supressão de uma infecção viral
PL370134A1 (en) Inhibitors of factor xa and other serine proteases involved in the coagulation cascade
BR9908280A (pt) Inibidores de enzimas de fosfolipase
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
FI935778A (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
EE03550B1 (et) ACE inhibiitorit ramipriili ja dihüdropüridiinühendit sisaldav ravimpreparaat ja selle valmistamise meetod
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
MY136141A (en) Novel hydantoin derivatives and pharmaceutical compositions useful as metalloproteinase inhibitors
DE69919397D1 (de) Thrombin-inhibitoren
MXPA03006224A (es) Inhibidores de cruzipaina y otras proteasas de cisteina.
WO2002028829A3 (fr) Inhibiteurs de peptide deformylase
ATE417617T1 (de) Mittel zur steurung der expression von il-12
BR9916255A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos de tratamento de uma condição em que se requer inibição de trombina e para a preparação de compostos
PL369725A1 (en) Pharmaceutical formulations containing low concentration of peroxide for treating or preventing vaginal infections
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
DK1053012T3 (da) Farmaceutiske sammensætninger omfattende PEG-asparaginase til behandling af HIV-infektioner
DK1213289T3 (da) N-benzensulfonyl-L-prolinforbindelser som bradykininantagonister
BR9811937A (pt) Método de aumentar a biodisponibilidade de fexofenadina e de seus derivados
ATE407116T1 (de) Neue amidino-derivate und deren verwendung als thrombin-inhibitoren
BR0206960A (pt) Composição farmacêutica oral, e, uso de um polìmero de ftalato de hidroxipropilmetilcelulose
BR0002512A (pt) Derivados de 4-arilpiperidina para o tratamento de prurido
WO2002030445A3 (fr) Fibrinogene plus inhibiteur de fibrinolyse n'agissant pas sur la plasmine pour reduire ou prevenir la formation d'adherences
ATE299027T1 (de) Verwendung von übersulfatierten polysacchariden als hiv-hemmer
ATE295168T1 (de) Zusammensetzung von riluzol und alpha-tocopherol